Product Information for Vets - Nobivac FeLV
Feline leukaemia is a major cause of death in young adult cats. The virus is commonly spread by close contact, between cats including cat fight wounds, or even licking and grooming. It is also transferred from an infected queen to her kittens while they are still in the womb. The time between infection with the virus and the appearance of signs of the disease may be very long – up to several years in some cases. Infected cats can appear healthy but still be a risk of infection to others.
Nobivac FeLV is an inactivated vaccine which contains 102 microgram per ml of purified p45 FeLV-envelope antigen, obtained by genetic recombination of a strain of E. coli. The antigenic suspension is adjuvanted with 0.1 ml of a 3% aluminium hydroxide gel and with 10 microgram purified extract of Quillaja saponaria. Nobivac FeLV is for the active immunisation of healthy unexposed cats and kittens against infection with feline leukaemia virus, thereby preventing viraemia and the diseases, including tumours, which may result from such infection. It is logical to assume that the vast majority of cats in Ireland lead an outdoor existence and are therefore at risk of feline leukaemia (in which case FeLV vaccination is certainly recommended). Indoor cats in multi-cat households may also benefit from the protection against FeLV that vaccination affords. For uses, dosage, contra-indications and warnings please consult product leaflet. Further information is available on request. Use medicines responsibly.
Cardboard boxes containing 10 or 50 single dose vials of vaccine.
Not all presentations may be marketed.